The role of miR-222 and miR-298 in breast cancer drug resistance

Jinyin Yan,Yang Zhang,Lukui Wang,Hao Dai,Ning Li,Wanning Hu,Haifeng Cai
2016-01-01
Abstract:Docetaxel is widely applied in the clinic for the treatment of breast cancer. However, drug resistance might appear for the long-term usage. It was considered that breast cancer drug resistance was related to the aberrant expressions of some miRNAs. This study explored the role of miR-222 and miR-298 in the development of docetaxel resistance in the treatment of breast cancer. A total of 45 cases of breast cancer patients with drug resistance were enrolled in this study. RT-PCR and in situ molecular hybridization were used to determine the expression of miR-222 and miR-298 in breast cancer tissues. Mimic and inhibitor transfections were performed on breast cancer cell line MCF-7 to manipulate the expressions of miR-222 and miR-298. MTT assay was adopted to evaluate MCF-7 cell drug resistance. Western blot was performed to analyze the expression of PTEN and MDR1. Our results showed that miR222 expression was significantly increased in breast cancer tissue with drug resistance, while miR-298 was obviously downregulated (P<0.05). Drug susceptibility test showed that miR-222 overexpression or miR-298 inhibition markedly enhanced drug resistance. In addition, miR-222 overexpression reduced PTEN level, whereas miR-298 inhibition elevated MDR1 expression. In conclusion, miR-222 was upregulated while miR-298 was declined in drug resistant breast cancer cells and they may regulate the development of drug resistance through targeting PTEN and MDR1.
What problem does this paper attempt to address?